Selected to Dispense XOSPATA

November 30, 2018

Selected to Dispense XOSPATA

Onco360® was selected as a specialty pharmacy network partner for Astellas’ new product XOSPATA® (gilteritinib) for the treatment of patients with relapsed or refractory FMS-like Tyrosine Kinase 3 (FLT3) mutation-positive acute myeloid leukemia (AML).

“Onco360 is excited to be selected as one of only three specialty pharmacy providers for XOSPATA patients,” said Paul Jardina, President and CEO, Onco360. “The recent approval of XOSPATA unlocks a new treatment option for AML patients with extremely limited treatment alternatives. As a provider of this key treatment, Onco360 can support the highly specialized needs of AML patients and their physicians across the states.”

AML is the most common form of acute leukemia in adults in the United States (U.S). Only 27 percent of patients diagnosed with AML survive for five years following initial diagnosis. FLT3 mutations occur in about 33 percent of AML patients and is an indicator of a poor prognosis. The American Cancer Society estimates that in 2018, approximately 19,500 new patients will be diagnosed with AML in the U.S.1 Previously, there were no U.S. Food and Drug Administration (FDA)-approved products for patients with relapsed or refractory FLT3 mutation-positive AML.

XOSPATA is a manufactured by Astellas Pharma Inc. and was approved by the U.S. FDA on November 28, 2018 based on positive clinical trial results.2 Full prescribing information can be found at Xospata.com.

XOSPATA is immediately available to order through Onco360. Referral forms and information on how to order can be found at Onco360.com/Order.

1American Cancer Society, www.cancer.org. Key Statistics for Acute Myeloid Leukemia (2018).

2Perl AE, et al. Lancet Oncol. 2017 Aug; 18(8): 1061-1075